Agenus share price logo

Agenus

NASDAQ: AGEN

Small Cap

$8.36

+0.03

(+0.36%)

as on

Agenus Stock Performance

as on October 3, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $8.09
    $8.60
    downward going graph

    3.23%

    Downside

    2.87%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $2.71
    $10.31
    downward going graph

    67.58%

    Downside

    23.33%

    Upside

    downward going graph

Agenus share price movements today

Previous Close
$8.33
Open
$8.44
Volume
975.9K
Market Cap
$376.2M
Day's Low - High
$8.09 - $8.60
52 Week Low - High
$2.71 - $10.31

Agenus Historical Returns

1 Month Return
+ 1.46 %
3 Month Return
+ 139.54 %
1 Year Return
+ 101.93 %
3 Year Return
-59.42 %
5 Year Return
-92.14 %

Agenus Stock Fundamentals & Key Indicators

Check Agenus market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$376.2M

EPS (TTM)

2.7154

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

3.25

Industry PE ratio

-6.16

PEG Ratio

0.00

EBITDA

155.8M

Revenue (TTM)

132.7M

Profit Margin

75.63%

Return On Equity TTM

-38.12%

Agenus vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Agenus with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$376.2M-92.14%3.2575.63%0.00%
StrongBuy$44.1B609.62%-23.340.00%0.00%
Neutral$75.4B-44.29%-24.08-12.57%0.00%
StrongBuy$132.5B180.98%30.1986.04%0.00%
Buy$78.1B28.80%17.6784.86%0.50%

Stock Returns calculator for Agenus Stock including INR - Dollar returns

The Agenus stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Agenus investment value today

Current value as on today

₹2,19,185

Returns

₹1,19,185

(+119.18%)

Returns from Agenus Stock

₹1,01,932 (+101.93%)

Dollar Impact

₹17,253 (+17.25%)

Analyst Recommendation on Agenus Stock

Based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for Agenus. Average target price of $26.33

Agenus Share Price Target

Get share price movements and forecasts by analysts on Agenus.

What analysts predicted

68.25%UPSIDE

Target Price

$26.33

Current Price

$8.36

Analyzed by

2 Analysts

High

$40

Target

$26.33

Low

$14

Agenus target price $26.33, a slight upside of 68.25% compared to current price of $8.36. According to 2 analysts rating.

Indian Investors' Interest in Agenus Stock

Search interest for Agenus Stock has decreased by -39% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-39% versus previous 30 day period

Agenus Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
28
23
25
26
24
25
30
34
33
34
Gross Profit
24
-13
-16
-7
2
-1
5
26
33
34
Operating Income
-32
-30
-31
-25
-13
-16
-4
14
15
11
EBITDA
-30
-19
-28
-22
-10
-13
80
6
54
15
Interest Expense
29
31
35
20
12
13
13
16
14
15
Depreciation
3
3
3
3
3
3
3
0
0
0
Income Before Tax
-63
-54
-67
-46
-26
-30
63
-10
39
0
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-61
-53
-66
-45
-25
-27
63
-10
39
0
Net Profit Margin
87.57%
-56.90%
-64.08%
-26.29%
10.00%
-4.91%
19.83%
78.04%
98.27%
100.00%

Agenus Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
42
36
150
88
295
98
156
103
114
Gross Profit
-73
-87
-18
-56
113
-99
-81
-52
33
Operating Income
-103
-123
-70
-117
25
-179
-159
-120
-20
EBITDA
-95
-130
-63
-114
43
-161
-145
-101
62
Interest Expense
18
25
41
61
65
61
97
117
55
Depreciation
6
6
6
7
6
6
13
13
9
Income Before Tax
-120
-162
-111
-182
-28
-230
-257
-232
-3
Income Tax Expense
-
-12
-
-
-
-
-
-
-
Net Income
-120
-159
-107
-180
-23
-220
-245
-227
0
Net Profit Margin
-170.83%
-238.74%
-12.19%
-64.42%
38.42%
-101.24%
-52.05%
-50.79%
29.63%

Agenus Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-63
-54
-67
-45
-26
-30
63
-10
39
0
Operating Cash Flow
-38
-38
-53
-28
-25
-20
-14
-16
-35
-31
Investing Cash Flow
0
0
0
0
0
0
0
0
68
0
Financing Cash Flow
14
79
4
24
3
10
6
15
0
14
Change in Cash
-23
40
-48
-4
-21
-8
-7
0
31
-16

Agenus Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-120
-162
-111
-182
-28
-230
-257
-232
-232
Operating Cash Flow
-94
-131
-18
-139
10
-175
-224
-158
-158
Investing Cash Flow
2
-3
-4
-4
-43
-33
3
0
0
Financing Cash Flow
80
128
31
183
225
95
119
122
122
Change in Cash
-11
-7
8
40
192
-113
-101
-35
-35

Global Institutional Holdings in Agenus

Check out the Institutions with significant holdings in Agenus.

Funds
Holdings
Vanguard
4.46%
iShares
3.25%
VANGUARD INDEX FUNDS
3.12%
TIAA-CREF Funds
2.24%
VANGUARD HORIZON FUNDS
1.59%

Agenus News & Key Events

  • img

    Today's Timeline - 13 July

    Tue, 07:04 AM

    -

    Agenus shares surged 82.69% after reporting positive Phase 1b data and announcing a $340 million private placement.

Insights on Agenus

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 33.73M → 34.51M (in $), with an average increase of 2.3% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, AGEN stock has moved up by 139.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 84.3% return, outperforming this stock by 143.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 566.9% return, outperforming this stock by 465.0%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 39.22M → -550.0K (in $), with an average decrease of 101.4% per quarter

About Agenus

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
OrganisationAgenus
Headquarters3 Forbes Road, Lexington, MA, 02421-7305, US
IndustryBiotechnology
CEOGaro H. Armen

Key Management of Agenus

Name

Title

Dr. Steven J. O'Day M.D., Ph.D.

Chief Medical Officer

Craig Winter

Chief Information Officer

Ms. Stefanie Perna-Nacar

Chief Communications & Government Relations Officer

Ms. Tracy Mazza Clemente

Chief People Officer

Dr. Todd Jude Yancey M.D.

Member of Advisory Board & Chief Strategic Advisor

Dr. Robin G. Taylor M.B.A., Ph.D.

Chief Commercial Officer

Dr. Kamel Djazouli M.D.

Head of Medical Affairs

Dr. Garo H. Armen Ph.D.

Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman

Dr. Jennifer S. Buell Ph.D.

Director and President & CEO of MiNK Therapeutics

Mr. Zack Armen

Vice President of Investor Relations & Corporate Development

FAQs

What is Agenus share price today?

Agenus share price today is $8.36 as on at the close of the market. Agenus share today touched a day high of $8.60 and a low of $8.09.

What is the 52 week high and 52 week low for Agenus share?

Agenus share touched a 52 week high of $10.31 on and a 52 week low of $2.71 on . Agenus stock price today i.e. is closed at $8.36,which is 18.91% down from its 52 week high and 208.49% up from its 52 week low.

What is Agenus's market capitalisation today?

Agenus market capitalisation is $0.00T as on .

How to invest in Agenus Stock (AGEN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Agenus on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Agenus Stock (AGEN) from India?

Indian investors can start investing in Agenus (AGEN) shares with as little as ₹96.300003051758 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹963.00 in Agenus stock (as per the Rupee-Dollar exchange rate as on ). Based on Agenus share’s latest price of $8.36 as on October 3, 2026 at 8:45 am IST, you will get 1.1962 shares of Agenus. Learn more about fractional shares .

What are the returns that Agenus has given to Indian investors in the last 5 years?

Agenus stock has given -92.14% share price returns and 28.69% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?